Budesonide orodispersible tablets are a new formulation of budesonide to treat eosinophilic oesophagitis in adults. Eosinophilic oesophagitis is an inflammatory condition that causes problems with eating and swallowing. Budesonide orodispersible tablets are dissolved in the mouth and slowly swallowed. Some studies have suggested that budesonide may reduce the inflammatory reaction that causes the symptoms of eosinophilic oesophagitis.
Filgotinib is in clinical development for the treatment of patients with moderately to severely active ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and ulcers in the bowel and rectum which can cause diarrhoea, abdominal pain and faecal urgency or incontinence. The symptoms of ulcerative colitis often follow a pattern of relapse and remission where they have periods of none or mild symptoms followed by periods of increased symptoms flare-up (‘active’). There are no curative therapies for ulcerative colitis and current treatment aims to relieve symptoms during a flare-up and maintain remission by preventing symptoms from returning.